These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38345741)

  • 1. Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study.
    Freire-Alvarez E; Vanni P; Kurča E; Lopez-Manzanares L; Kovács N; Spanaki C; Gao T; Bergmann L; Sánchez-Soliño O
    Neurol Ther; 2024 Apr; 13(2):437-447. PubMed ID: 38345741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Freire-Alvarez E; Kurča E; Lopez Manzanares L; Pekkonen E; Spanaki C; Vanni P; Liu Y; Sánchez-Soliño O; Barbato LM
    Mov Disord; 2021 Nov; 36(11):2615-2623. PubMed ID: 34236101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study.
    Chung SJ; Calopa M; Ceravolo MG; Tambasco N; Antonini A; Chaudhuri KR; Robieson WZ; Sánchez-Soliño O; Zadikoff C; Jin M; Barbato LM
    Parkinsons Dis; 2022; 2022():1216975. PubMed ID: 36388237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
    Pahwa R; Fox S; Hauser RA; Isaacson S; Lytle J; Johnson R; Llorens L; Formella AE; Tanner CM
    Front Neurol; 2022; 13():846126. PubMed ID: 36341088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies.
    Boyd JT; Zadikoff C; Benesh JA; Zamudio J; Robieson WZ; Kukreja P; Yokoyama M; Siddiqui MS
    Clin Park Relat Disord; 2020; 2():25-34. PubMed ID: 34316616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
    Fernandez HH; Vanagunas A; Odin P; Espay AJ; Hauser RA; Standaert DG; Chatamra K; Benesh J; Pritchett Y; Hass SL; Lenz RA
    Parkinsonism Relat Disord; 2013 Mar; 19(3):339-45. PubMed ID: 23287001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
    Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.
    Standaert DG; Aldred J; Anca-Herschkovitsch M; Bourgeois P; Cubo E; Davis TL; Iansek R; Kovács N; Pontieri FE; Siddiqui MS; Simu M; Bergmann L; Kukreja P; Robieson WZ; Chaudhuri KR
    Mov Disord Clin Pract; 2021 Oct; 8(7):1061-1074. PubMed ID: 34631942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
    Chaudhuri KR; Antonini A; Pahwa R; Odin P; Titova N; Thakkar S; Snedecor SJ; Hegde S; Alobaidi A; Parra JC; Zadikoff C; Bergmann L; Standaert DG
    J Parkinsons Dis; 2022; 12(7):2071-2083. PubMed ID: 35964203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Duodopa
    Ciurleo R; Corallo F; Bonanno L; Lo Buono V; Di Lorenzo G; Versaci R; Allone C; Palmeri R; Bramanti P; Marino S
    J Neurol; 2018 Sep; 265(9):2005-2014. PubMed ID: 29951701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
    Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
    Kovács N; Bergmann L; Anca-Herschkovitsch M; Cubo E; Davis TL; Iansek R; Siddiqui MS; Simu M; Standaert DG; Chaudhuri KR; Bourgeois P; Gao T; Kukreja P; Pontieri FE; Aldred J
    J Parkinsons Dis; 2022; 12(3):917-926. PubMed ID: 34974438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease.
    Murata M; Mihara M; Hasegawa K; Jeon B; Tsai CH; Nishikawa N; Oeda T; Yokoyama M; Robieson WZ; Chatamra K; Facheris MF; Benesh J
    Ther Adv Neurol Disord; 2018; 11():1756286418759315. PubMed ID: 29511383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
    Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
    Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial.
    Pahwa R; Aldred J; Merola A; Gupta N; Terasawa E; Garcia-Horton V; Steffen DR; Kandukuri PL; Bao Y; Ladhani O; Yan CH; Chaudhari V; Isaacson SH
    Clin Park Relat Disord; 2023; 8():100181. PubMed ID: 36594071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.